证券代码：603367 证券简称：辰欣药业 公告编号：2025-055 辰欣药业股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 每股分配比例 A股每股现金红利0.18800元（含税） 一、通过分配方案的股东会届次和日期 本次利润分配方案经公司2025年5月20日的2024年年度股东大会审议通过。公司于2025年5月20日召开的 2024年年度股东大会审议通过了《公司关于提请股东大会授权董事会决定2025年中期分红方案的议 案》，授权董事会制定2025年中期分红方案。2025年8月27日，公司第五届董事会第九次会议审议通过 了《关于公司2025年半年度利润分配方案的议案》。 二、分配方案 1.发放年度：2025年半年度 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分公司（以下简 称"中国结算上海分公司"）登记在册的本公司全体股东。 3.分配方案： 本次利润分配以方案实施前的公司总股本452,754,129股为基数，每 ...

（编辑 姚尧） 证券日报网讯 9月26日晚间，辰欣药业发布公告称，2025年半年度利润分配方案为A股每股现金红利 0.188元（含税），股权登记日为2025年10月10日，除权（息）日为2025年10月13日。 ...

证券代码：603367 证券简称：辰欣药业 公告编号：2025-055 辰欣药业股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.18800元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/10/10 | － | 2025/10/13 | 2025/10/13 | 差异化分红送转： 否 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 5 月 20 日的2024年年度股东大会审议通过。公司于 2025 年 5 月 20 日召开的 2024 年年度股东大会审议通过了《公司关于提请股东大会授权董事会决 定 2025 年中期分红方案的议案》，授权董事会制定 2025 年中期分红方案。2025 年 8 月 27 日， 公司第五届董事会第九次会议审议通过了《关于公司 20 ...

Group 1 - The major shareholder, Shijiazhuang Four Pharmaceutical Co., Ltd. (Stone Four Pharmaceutical), held 27,661,441 shares of Chenxin Pharmaceutical, accounting for 6.11% of the total share capital before the reduction plan [1] - The reduction plan announced on August 30, 2025, indicated that Stone Four Pharmaceutical intended to reduce its holdings by up to 4,527,000 shares, which is 1.00% of the total shares [1] - As of September 22, 2025, Stone Four Pharmaceutical reduced its holdings by 1,000,000 shares, bringing its total holdings down to 26,661,441 shares, which is 5.89% of the total share capital [2] Group 2 - By September 24, 2025, Stone Four Pharmaceutical had completed its reduction plan, having cumulatively reduced its holdings by 4,520,000 shares, representing 0.998% of the total share capital [2][4] - The actual reduction was consistent with the previously disclosed reduction plan, and the plan was fully implemented without any early termination [4]

Group 1 - The major shareholder, Shijiazhuang Four Pharmaceutical Co., Ltd., held 27,661,441 shares of Chenxin Pharmaceutical, accounting for 6.11% of the total share capital before the reduction plan [2] - The reduction plan was disclosed on August 30, 2025, with a maximum reduction of 4,527,000 shares, representing 1.00% of the total shares [3] - As of September 24, 2025, the major shareholder had reduced its holdings by 4,520,000 shares, bringing the total shareholding down to 26,661,441 shares, which is 5.89% of the total [3][5] Group 2 - The reduction plan was fully implemented, and the actual reduction matched the previously disclosed plan [5] - There were no concerted actions among the major shareholder [4] - The reduction was completed within the specified time frame without any early termination of the plan [5]

Group 1 - The core point of the article is that Shijiazhuang Four Drug Co., Ltd. has completed a share reduction plan for its holdings in Chenxin Pharmaceutical, reducing its stake from 6.11% to 5.11% [2][2] - Before the reduction, Shijiazhuang Four Drug held 27,661,441 shares of Chenxin Pharmaceutical, which accounted for 6.11% of the total share capital [2][2] - As of September 24, 2025, Shijiazhuang Four Drug has reduced its holdings by 4,520,000 shares, representing 0.998% of the total share capital of Chenxin Pharmaceutical [2][2]

Group 1 - The company, Chenxin Pharmaceutical, announced on September 24, 2025, that it received a notification from Shisi Pharmaceutical regarding the completion of a share reduction plan, where Shisi Pharmaceutical reduced its holdings by 4,520,000 shares, accounting for 0.998% of the total share capital [1][1][1] - For the year 2024, Chenxin Pharmaceutical's revenue composition indicates that the pharmaceutical manufacturing sector contributed 99.75% to the total revenue, while other businesses accounted for only 0.25% [1][1][1] - As of the report date, Chenxin Pharmaceutical has a market capitalization of 9.3 billion yuan [1][1][1] Group 2 - The A-share market reached a total market value of over 116 trillion yuan on the anniversary of the "9.24" event, indicating significant changes in the Chinese capital market [1][1][1]

证券代码：603367 证券简称：辰欣药业 公告编号：2025-054 辰欣药业股份有限公司 1 一、减持主体减持前基本情况 关于持股 5%以上股东减持股份计划完成暨减持股份 结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 持股 5%以上股东持股的基本情况 本次减持计划实施前，辰欣药业股份有限公司（以下简称"公司"或"辰欣 药业"）持股 5%以上股东石家庄四药有限公司（以下简称"石四药"）持有辰 欣药业无限售流通股份 27,661,441 股，占辰欣药业总股本的 6.11%。前述股份 来源为石四药通过协议转让取得的股份。 减持计划的实施结果情况 公司于 2025 年 8 月 30 日披露了《辰欣药业股份有限公司关于持股 5%以上 股东减持股份计划公告》（公告编号：2025-047），石四药计划通过集中竞价交易 方式减持合计不超过公司股份总数的 1.00%（即不超过 4,527,000 股）。 2025 年 9 月 23 日，公司收到持股 5%以上股东石四药出具的《股份减持情况 告知函》，获悉 ...

Group 1 - The core point of the article is that Chenxin Pharmaceutical (603367.SH) has completed a share reduction plan initiated by Shisi Pharmaceutical, resulting in a total reduction of 4.52 million shares, which represents 0.998% of the company's total share capital [1] Group 2 - The share reduction was executed through centralized bidding transactions [1] - The completion date of the share reduction plan is September 24, 2025 [1] - The report indicates that the share reduction plan has been fully implemented [1]

Core Viewpoint - The major shareholder, Shijiazhuang Four Pharmaceutical Co., Ltd., has completed its share reduction plan, which was in line with its previously disclosed intentions [1] Summary by Relevant Sections Shareholder Reduction - Shijiazhuang Four Pharmaceutical Co., Ltd. held 27,661,441 unrestricted circulating shares before the reduction, accounting for 6.11% of the total share capital [1] - The reduction plan was announced on August 30, 2025, with a target to reduce no more than 4,527,000 shares through centralized bidding [1] - As of September 24, 2025, Shijiazhuang Four Pharmaceutical Co., Ltd. had cumulatively reduced 4,520,000 shares, representing 0.998% of the total share capital [1] Financial Details - The share reduction occurred at a price range of 19.70 to 21.17 yuan per share, resulting in a total reduction amount of 91,220,564 yuan [1] - Post-reduction, Shijiazhuang Four Pharmaceutical Co., Ltd. holds 23,141,441 shares, which is 5.11% of the total share capital [1] Compliance with Plan - The reduction was executed as planned and was not terminated early [1]